- Home
- SRV vs ADAG Comparison
SRV vs ADAG Comparison
Compare SRV & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRV | ADAG |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.9M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRV | ADAG |
|---|---|---|
| Price | $38.60 | $1.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 33.9K | ★ 80.3K |
| Earning Date | 01-01-0001 | 08-12-2025 |
| Dividend Yield | ★ 13.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | N/A | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.73 | $1.30 |
| 52 Week High | $44.30 | $3.16 |
Technical Indicators
Market Signals| Indicator | SRV | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 30.34 | 49.36 |
| Support Level | $39.28 | $1.61 |
| Resistance Level | $40.30 | $1.92 |
| Average True Range (ATR) | 0.70 | 0.15 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 5.35 | 53.40 |
Price Performance
Historical ComparisonAbout SRV NXG Cushing Midstream Energy Fund of Beneficial Interest
NXG Cushing Midstream Energy Fund is a non-diversified, closed-end management investment company with an investment objective of seeking a high after-tax total return from a combination of capital appreciation and current income. The fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in midstream energy investments.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.